Jacqueline Cloos
Jacqueline Cloos
Research coordinator, Hematology, VU University Medical Center,
Verified email at - Homepage
Cited by
Cited by
Cell sensitivity assays: the MTT assay
J Van Meerloo, GJL Kaspers, J Cloos
Cancer cell culture: methods and protocols, 237-245, 2011
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
GJ Schuurhuis, M Heuser, S Freeman, MC Béné, F Buccisano, J Cloos, ...
Blood, The Journal of the American Society of Hematology 131 (12), 1275-1291, 2018
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features
M Kool, J Koster, J Bunt, NE Hasselt, A Lakeman, P Van Sluis, D Troost, ...
PloS one 3 (8), e3088, 2008
Molecular minimal residual disease in acute myeloid leukemia
M Jongen-Lavrencic, T Grob, D Hanekamp, FG Kavelaars, A Al Hinai, ...
New England Journal of Medicine 378 (13), 1189-1199, 2018
Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein
R Oerlemans, NE Franke, YG Assaraf, J Cloos, I van Zantwijk, CR Berkers, ...
Blood, The Journal of the American Society of Hematology 112 (6), 2489-2499, 2008
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia
K De Keersmaecker, ZK Atak, N Li, C Vicente, S Patchett, T Girardi, ...
Nature genetics 45 (2), 186-190, 2013
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
M Heuser, SD Freeman, GJ Ossenkoppele, F Buccisano, CS Hourigan, ...
Blood, The Journal of the American Society of Hematology 138 (26), 2753-2767, 2021
In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma
SE Mir, PCDW Hamer, PM Krawczyk, L Balaj, A Claes, JM Niers, ...
Cancer cell 18 (3), 244-257, 2010
Molecular signature associated with bone marrow micrometastasis in human breast cancer
U Woelfle, J Cloos, G Sauter, L Riethdorf, F Jänicke, P Van Diest, ...
Cancer research 63 (18), 5679-5684, 2003
miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis
M Smits, J Nilsson, SE Mir, PM van der Stoop, E Hulleman, JM Niers, ...
Oncotarget 1 (8), 710, 2010
Genetic susceptibility to head and neck squamous cell carcinoma
J Cloos, MR Spitz, SP Schantz, TC Hsu, Z Zhang, H Tobi, BJM Braakhuis, ...
JNCI: Journal of the National Cancer Institute 88 (8), 530-535, 1996
Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells
NE Franke, D Niewerth, YG Assaraf, J van Meerloo, K Vojtekova, ...
Leukemia 26 (4), 757-768, 2012
Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML
IHIM Hollink, CM Zwaan, M Zimmermann, T Arentsen-Peters, R Pieters, ...
Leukemia 23 (2), 262-270, 2009
Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples
J Cloos, BF Goemans, CJ Hess, JW Van Oostveen, Q Waisfisz, S Corthals, ...
Leukemia 20 (7), 1217-1220, 2006
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia
I Hubeek, RW Stam, GJ Peters, R Broekhuizen, JPP Meijerink, ...
British journal of cancer 93 (12), 1388-1394, 2005
Molecular basis of resistance to proteasome inhibitors in hematological malignancies
D Niewerth, G Jansen, YG Assaraf, S Zweegman, GJL Kaspers, J Cloos
Drug resistance updates 18, 18-35, 2015
CD34+CD38 leukemic stem cell frequency to predict outcome in acute myeloid leukemia
W Zeijlemaker, T Grob, R Meijer, D Hanekamp, A Kelder, ...
Leukemia 33 (5), 1102-1112, 2019
Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia
Z Kalender Atak, V Gianfelici, G Hulselmans, K De Keersmaecker, ...
PLoS genetics 9 (12), e1003997, 2013
The role of alternative splicing in cancer: From oncogenesis to drug resistance
R Sciarrillo, A Wojtuszkiewicz, YG Assaraf, G Jansen, GJL Kaspers, ...
Drug Resistance Updates 53, 100728, 2020
Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia
BV Balgobind, IHIM Hollink, ST Arentsen-Peters, M Zimmermann, ...
haematologica 96 (10), 1478, 2011
The system can't perform the operation now. Try again later.
Articles 1–20